Reuters logo
BRIEF-Basilea Pharmaceutica: agreement with FDA regarding ceftobiprole
April 21, 2017 / 5:28 AM / 7 months ago

BRIEF-Basilea Pharmaceutica: agreement with FDA regarding ceftobiprole

April 21 (Reuters) - Basilea Pharmaceutica AG:

* Basilea announces agreement with FDA on special protocol assessments for antibiotic ceftobiprole phase 3 clinical studies in bloodstream and skin infections

* Initiation of ceftobiprole pivotal phase 3 clinical program under barda contract anticipated within next three to six months Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below